Senior Scientist 1/2
Gordian Biotechnology
Senior Scientist 1/2
Gordian Biotechnology
Biotech firm developing aging-related therapies
Are you ready to own the in vivo work behind one or two of Gordian's disease programs, from the screens that generate novel targets, through the studies that decide which ones advance, to the experiments that support turning them into drugs?
Gordian is the leader in applying in vivo screening for target discovery. Almost everything we know that our competitors do not, we learned inside a living animal. As a Senior Scientist in our in vivo team, you will own target validation for your disease programs, design and run the experiments that decide which targets go into drug discovery, and lead a small team from the bench.
Gordian Biotechnology is a therapeutics company designed as a machine that systematically
reveals the right way to cure age-related diseases: a machine for creating time.
To do that, we built Mosaic Screening, which makes causal validation both grounded in human
pathophysiology and radically more scalable in living diseased tissue. It lets us measure the causal effects of hundreds of perturbations directly in vivo, which reveals therapeutic maxima across vast target spaces (more details on our website and in our preprint). The machine is already producing wins: across six disease areas, we have mapped nearly as many targets as the field reported in 20 years, advanced a novel osteoarthritis candidate into IND-enabling studies, and started an obesity drug-discovery collaboration with Pfizer.
But there are still many diseases left to cure, and expanding the machine to tackle them starts with its most important resource: its people and culture. We work as a team, using clear goals, open communication, and direct feedback to make autonomous decisions with the bigger picture in mind. We aim for extraordinary outcomes, continually improving how we work and acting on what will create the most progress, even in unknown territory. We have deliberately designed an environment to sustain that standard: few standing meetings, hands-on experimentation and pre-mortems, weekly team lunches, and unlimited vacation that people are encouraged to use. You can dive deeper into our culture here.
This way of working has been crucial to Gordian’s success.
Your mission is to make sure we find and select the best targets for drug discovery in your disease programs. You will own one or two programs (for example obesity, chronic kidney disease, heart failure with preserved ejection fraction, or others) across three connected workstreams:
You design the experiments for your programs: model, modality, dose, route, controls, timepoints, group size and statistical power. You default to a pilot before a large cohort and to establishing exposure and pharmacodynamics before efficacy, and you say clearly what each design can and cannot conclude. Your designs are reviewed against portfolio-wide standards set by our VP of Biology.
You will choose among oligonucleotides, AAV and small molecules according to what each question requires, and you will set up new disease models, delivery routes and readouts when existing ones cannot answer the question.
You care about which targets we advance, not just whether studies get run. You will work closely with the screening, computational, ex vivo and assay, and medicinal chemistry teams, and present results so they can act on them: what the data shows, what it does not show, and which decision it supports.
You will lead a team of research associates and senior research associates, run the weekly in vivo meeting, and own vivarium operations and IACUC compliance through our Vivarium Manager.
One thing to be clear about: this is a leadership role that is led from the bench. You will spend roughly 50–70% of your time in the lab. You will run studies yourself, teach every technique until your team runs it reliably, hand it over, and then set up the next technique, model or readout. That time at the bench is not a formality: it is how you set the standard, catch problems before they become data, and know first-hand what is true. You will also take a real share of crunch-time work, such as dosing and takedowns, and join the weekend check rotation.
In your first month, learn Gordian's platform and our in vivo obesity work; personally run dosing and a takedown in our vivarium; start weekly one-to-ones with your team and the Vivarium Manager; run the weekly in vivo meeting; and be able to explain where each of your programs stands and the next decision it needs.
By two months, understand our heart failure and kidney work; join the weekend check rotation; and own day-to-day study design, protocols and vivarium operations without relying on anyone else.
By three months, have a written target validation plan for each of your programs, covering targets, evidence bar, studies, timelines and resources; document, teach and hand over at least one core technique; and run the in vivo work for our major pharma partnership to plan.
By six months, deliver decision-ready validation data and a recommendation for at least one target in your programs; have screen and drug discovery work in your areas delivering to schedule with no study repeated because of a design or execution error; set up and validate one new technique, model or readout; and have at least one team member owning a study end to end.
You have a track record of success in high-agency work, consistently creating momentum rather than waiting for direction.
You want to do your best work alongside exceptional teammates and are energized by environments where people push each other to think more clearly, work at a higher standard, and grow into better versions of themselves.
You truly want to play a key role in an early-stage startup validating new targets for intractable diseases of aging: a fast-paced environment full of both uncertainty and new challenges, demanding relentless resourcefulness.
You have cardiometabolic or renal in vivo expertise. You have personally run and interpreted rodent obesity and metabolic efficacy studies (DIO and/or genetic models), and/or heart failure, kidney or atherosclerosis models, where the result drove a real decision. You have a PhD and 3–7 years of in vivo work in industry discovery programs, or equivalent depth from longer industry experience.
You are expert with your hands, and you want to stay that way. You have personally run mouse and rat studies for around ten years, including your training: dosing (IP, PO, SC, IV), blood collection, takedowns and tissue harvest. You can tell good technique from bad on sight, teach it, and diagnose a study that is not working, and you want to keep spending most of your week at the bench.
You design target validation studies well. You have designed in vivo studies whose results decided whether a target advanced or stopped. You size groups from power calculations rather than habit, choose controls and timepoints that make a result interpretable, and think about which targets are best for drug discovery, not only how to run the next study.
You grow the people around you. You have trained others to run techniques reliably, ideally with SOPs and competency checks, and you take real satisfaction in seeing them succeed. Experience managing research associates is a strong plus.
You communicate so that decisions follow. You can explain a result and its limits to biology, chemistry and computational colleagues, push back on a study that will not answer the question, and present data clearly to partners.
This is an onsite leadership role in South San Francisco because regular laboratory presence is central to the work. Gordian offers meaningful equity, a competitive salary, full health, dental, vision, and life insurance, a 401(k) with match, onsite lunch three days a week, an onsite gym, an unlimited vacation policy, and access to world-class mentors and advisors.
[{'location': 'South San Francisco', 'currency': 'USD', 'frequency': 'YEAR', 'rangeStart': 138000.0, 'rangeEnd': 208000.0, 'isRemote': False}]
Biotech firm developing aging-related therapies
Gordian Bio develops and licenses therapies aimed at age-related diseases by focusing on aging biology. It uses advanced laboratory models to study aging processes and test potential treatments in settings that resemble human conditions. The company emphasizes gene therapy and genome engineering to create therapies, and collaborates with pharmaceutical companies, research institutions, and healthcare providers through partnerships and licensing deals. Its approach centers on using animal models, such as fruit flies, to scale aging research and improve the relevance of findings for human health. This helps them move therapies toward clinical use by validating treatments in conditions closer to human biology. The company’s goal is to extend healthy human lifespan by addressing the root causes of aging-related diseases, ultimately improving healthspan for people.
Explore more opportunities at Gordian Biotechnology